To evaluate whether incorporating locoregional radiotherapy in the treatment of oligometastatic renal cell carcinoma, including inductive oligometastases, along with standard systemic therapy, contributes to improved progression-free survival rates for patients.
Patients with metastatic renal cell carcinoma classified within the ESTRO/EORTC classification system as having ≤ 5 metastases, ≤ 3 metastatic organs, and meeting criteria for new, recurrent, or induced metastases.
Patients aged 20 to 80 years.
Patients with individual metastases ≤ 5 cm in longest diameter.
Patients with primary tumors surgically removed or scheduled for surgery.
Patients with total bilirubin > 3.6 mg/dL.
Patients with AST >160 U/L, ALT > 165 U/L.
Patients unable to maintain position for partial nephrectomy radiotherapy.
Patients with a history of radiotherapy to metastatic renal cell carcinoma or surrounding areas.